埃诺格鲁肽(Ecnoglutide) - 药物靶点：GLP-1R_在研适应症：2型糖尿病，肥胖，阻塞性睡眠呼吸暂停综合征_专利_临床

概要

基本信息

药物类型

重组蛋白

别名

Recombinant human glucagon-like peptide-1 analogue、伊诺格鲁肽、IN-B00009

+ [9]

靶点

GLP-1R

作用方式

激动剂

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病神经系统疾病呼吸系统疾病+ [1]

在研适应症

非在研适应症

原研机构

在研机构

HK inno.N Corp.Sciwind Biosciences USA Co., Ltd.

+ [1]

非在研机构-

权益机构

Verdiva Bio Ltd.

杭州先为达生物科技股份有限公司

辉瑞（中国）研究开发有限公司

+ [1]

最高研发阶段批准上市

首次获批日期

中国 (2026-01-27),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 452883170

来源: *****

关联

20

项与埃诺格鲁肽相关的临床试验

NCT07387094

/ Not yet recruiting临床3期

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy

The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA but not receiving PAP

开始日期2026-03-03

申办/合作机构

杭州先为达生物科技股份有限公司

NCT07308184

/ Not yet recruiting临床3期

A Multi-center, Randomized, Double-Blind, Placebo Controlled, Parallel, Phase 3 Bridge Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Patients With T2DM Inadequately Controlled by Diet and Exercise Alone

This Phase 3 Bridge study is designed to evaluate the efficacy and safety of IN-B00009 Injection in Patients with T2DM Inadequately Controlled by Diet and Exercise Alone

开始日期2025-12-01

申办/合作机构

HK inno.N Corp.

NCT07281937

/ Recruiting临床2期

A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.

开始日期2025-11-25

申办/合作机构-

100 项与埃诺格鲁肽相关的临床结果

登录后查看更多信息

100 项与埃诺格鲁肽相关的转化医学

登录后查看更多信息

100 项与埃诺格鲁肽相关的专利（医药）

登录后查看更多信息

21

项与埃诺格鲁肽相关的文献（医药）

2025-10-01·Lancet Diabetes & Endocrinology

Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?

Article

作者: Scheen, André J

2025-10-01·Lancet Diabetes & Endocrinology

Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial

Article

作者: Han, Jie ; Li, Qingju ; Guo, Mengying ; Cheng, Zhifeng ; Pan, Hai ; Zheng, Qing ; Zhou, Yanqin ; Wang, Huihui ; Zhu, Yikun ; Yang, Ming ; Li, Feng ; Guan, Lei ; Wu, Jun ; Ning, Jing ; Zhao, Shuping ; Duan, Binhong ; Shi, Xiaoguang ; Jiang, Feifei ; Mi, Nianrong ; Li, Xiaoying ; He, Yang ; Bing, Shaohui ; Yang, Liu ; Wang, Xin ; Li, Yao ; Wang, Su ; Guo, Wanjun ; Ling, Hongwei ; Bu, Yue ; Xue, Haibo ; Wang, Haifang

BACKGROUND:

Ecnoglutide is a novel biased GLP-1 receptor agonist that preferentially activates the cAMP pathway over β-arrestin recruitment. We aimed to assess both non-inferiority and superiority of ecnoglutide versus dulaglutide, also a GLP-1 receptor agonist, in patients with type 2 diabetes.

METHODS:

We conducted a 52-week, open-label, active-controlled, phase 3 trial at 52 hospitals in China. Adults aged 18-75 years with a BMI of 20-35 kg/m², a diagnosis of type 2 diabetes, and elevated glucose concentrations on metformin monotherapy were included. Participants were randomly assigned (1:1:1) to receive subcutaneous ecnoglutide (0·6 mg or 1·2 mg) or dulaglutide (1·5 mg) once weekly. The primary endpoint was mean change from baseline in HbA_1c at week 32 (non-inferiority for ecnoglutide 0·6 mg and 1·2 mg, with a 0·4% non-inferiority margin; superiority for ecnoglutide 1·2 mg) and was assessed in all randomly assigned participants who received at least one dose of study treatment (full analysis set). Safety was assessed in all randomly assigned participants who received at least one dose of study drug and had at least one safety evaluation after starting treatment. This trial is registered with ClinicalTrials.gov (NCT05680129) and has ended.

FINDINGS:

Between Jan 10 and May 30, 2023, 623 participants were randomly assigned, of whom 621 comprised the full analysis set (mean age 53·9 years [SD 10·1], 347 [56%] males, 274 [44%] females, and mean HbA_1c 8·40% [SD 0·78]; 68·28 mmol/mol [8·56]; 206 in the ecnoglutide 0·6 mg group, 208 in the ecnoglutide 1·2 mg group, and 207 in the dulaglutide 1·5 mg group). At week 32, mean HbA_1c reductions were 1·91% (SE 0·05; -20·86 mmol/mol [0·53]) with ecnoglutide 0·6 mg, 1·89% (0·05; -20·69 mmol/mol [0·54]) with ecnoglutide 1·2 mg, and 1·65% (0·05; -18·02 mmol/mol [0·53]) with dulaglutide. Estimated treatment differences versus dulaglutide were -0·26% (95% CI -0·39 to -0·13; -2·84 mmol/mol [-4·29 to -1·38]) with ecnoglutide 0·6 mg and -0·24% (-0·38 to -0·11; -2·67 mmol/mol [-4·14 to -1·20]; p=0·0002 for superiority) with ecnoglutide 1·2 mg. HbA_1c reductions were sustained to week 52. During the 52 weeks, six (3%) of 206 patients in the ecnoglutide 0·6 mg group, eight (4%) of 208 patients in the ecnoglutide 1·2 mg group, and six (3%) of 207 patients in the dulaglutide group discontinued treatment due to adverse events.

INTERPRETATION:

Once-weekly ecnoglutide 0·6 mg and 1·2 mg were non-inferior to dulaglutide 1·5 mg in reducing HbA_1c in adults with type 2 diabetes and elevated glucose concentrations on metformin monotherapy. Although the 1·2 mg dose showed statistically significantly greater reductions in HbA_1c from baseline to week 32 than dulaglutide 1·5 mg, the difference was not considered clinically relevant. Both doses of ecnoglutide were well tolerated. These results suggest that ecnoglutide might offer a new treatment option for type 2 diabetes.

FUNDING:

Hangzhou Sciwind Biosciences.

2025-09-01·Lancet Diabetes & Endocrinology

Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Article

作者: Wen, Binhong ; Guo, Mengying ; Guo, Tonglan ; Fu, Wenyan ; Tian, Junhang ; Zheng, Qing ; Yang, Ming ; Pan, Hai ; Lian, Qiufang ; Gao, Leili ; Gao, Ge ; Zhang, Yawei ; Ning, Jing ; Wang, Haifang ; Shi, Bimin ; Hu, Wen ; Shi, Xiaoguang ; Wang, Kun ; Ji, Linong ; Xing, Ying ; Lu, Yibing ; Li, Ya ; Li, Yao ; Huang, Chongbing ; Han, Jie ; Li, Qingju ; Jiang, Hongwei ; Yuan, Mingxia ; Xue, Haibo

BACKGROUND:

Ecnoglutide is a novel cyclic adenosine monophosphate (cAMP)-biased GLP-1 receptor agonist currently in development for weight management. We aimed to assess the efficacy and safety of once weekly ecnoglutide versus placebo for the treatment of overweight or obesity in Chinese adults.

METHODS:

This randomised, double-blind, placebo-controlled, phase 3 trial was done at 36 medical centres across China. Eligible adults were aged 18-75 years with overweight or obesity (defined as BMI ≥28 kg/m² or ≥24 kg/m² with at least one weight-related comorbidity [prediabetes, hypertension, hyperlipidaemia, metabolic dysfunction-associated steatotic liver disease, obstructive sleep apnoea syndrome, or weight-bearing joint pain]), without diabetes (type 1 or 2). Participants were randomly assigned (3:3:3:1:1:1) via computer-generated random sequencing to receive subcutaneous ecnoglutide (1·2, 1·8, or 2·4 mg) or volume-matched placebo (1·2, 1·8, or 2·4 mg), once weekly, stratified by BMI at screening (≥28 kg/m² and <28 kg/m²). The coprimary endpoints were percentage change in bodyweight and proportion of participants with a reduction in bodyweight of 5% or more at week 40 (using the treatment policy estimand in the full analysis set). The full analysis set included all randomly assigned participants who were exposed to at least one dose of study drug or placebo according to their assigned treatment group. Safety was assessed in all participants who received at least one dose and had a safety assessment after medication. This study was registered with ClinicalTrials.gov, NCT05813795, and is complete.

FINDINGS:

Between April 5, 2023, and June 20, 2024, 882 participants were screened and 664 were randomly assigned to receive ecnoglutide 1·2 mg (n=166), ecnoglutide 1·8 mg (n=166), ecnoglutide 2·4 mg (n=167), or placebo (n=165). At week 40, the least-squares mean percentage change in bodyweight was -9·1% (SE 0·8) in the ecnoglutide 1·2 mg group, -10·9% (0·9) in the ecnoglutide 1·8 mg group, and -13·2% (0·8) in the ecnoglutide 2·4 mg group versus 0·1% (0·8) in the placebo group, and the respective estimated treatment differences compared with placebo were -9·2% (97% CI -11·0 to -7·5), -11·1% (-13·1 to -9·1), and -13·3% (-15·3 to -11·3), respectively (all p<0·0001). The proportion of participants who achieved at least a 5% reduction in bodyweight at week 40 was 77% in the ecnoglutide 1·2 mg group, 84% in the ecnoglutide 1·8 mg group, and 87% in the ecnoglutide 2·4 mg group versus 16% of participants in the placebo group, and the respective estimated treatment differences versus placebo were 60% (98% CI 50 to 71), 68% (58 to 78), and 70% (61 to 80; all p<0·0001). Treatment-emergent adverse events were observed in 155 (93%) of 166 participants in the ecnoglutide 1·2 mg group, 154 (93%) of 166 participants in the ecnoglutide 1·8 mg group, 156 (93%) of 167 participants in the ecnoglutide 2·4 mg group, and 139 (84%) of 165 participants in the placebo group. The most common adverse events were mild-to-moderate gastrointestinal related events. Ten participants treated with ecnoglutide discontinued treatment due to adverse events.

INTERPRETATION:

In adults with obesity or overweight without diabetes (type 1 or 2), individuals administered ecnoglutide had superior and sustained reduction in bodyweight versus placebo with a favourable safety profile, supporting its potential use for weight management.

FUNDING:

Hangzhou Sciwind Biosciences.

346

项与埃诺格鲁肽相关的新闻（医药）

2026-02-26

·药生态

2个创新药企，分别达成BD合作

马年开工，国内2家创新药企，分别达成BD合作：先为达生物与辉瑞中国就埃诺格鲁肽注射液达成商业化战略合作协议 2026年2月24日，杭州先为达生物科技股份有限公司（简称“先为达生物”）与辉瑞中国今日宣布，双方就新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液（英文：Ecnoglutide injection，简称：埃诺格鲁肽）达成商业化战略合作协议。根据协议，辉瑞将获得该产品在中国大陆的独家商业化权益，迈出其全球代谢领域战略布局在中国的第一步；同时先为达生物为许可产品的药品上市许可持有人（MAH），负责许可产品的研发、注册、生产及供应。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付款。埃诺格鲁肽是由先为达生物自主研发的新一代cAMP偏向型GLP-1受体激动剂，将为2型糖尿病及长期体重管理相关患者提供更为精准的治疗方案。凭借独特的偏向性机制，埃诺格鲁肽注射液在多项临床研究中展现出了优异的疗效与安全性，其中国人群经安慰剂组调整后的平均体重降幅达15.1%，92.8%的患者达到具有临床意义的体重下降，超过80%的患者血糖达标（HbA1c<7.0%）。埃诺格鲁肽注射液已于2026年1月获得国家药品监督管理局（NMPA）批准上市用于成人2型糖尿病的治疗，其成人长期体重管理适应症的上市许可申请已获NMPA受理。关于先为达生物先为达生物是一家商业化阶段的生物医药公司，致力于满足体重管理领域的迫切医疗需求。先为达生物拥有偏向型激动剂发现平台、口服肽给药平台、半衰期延长平台，并基于这三大核心技术平台确立了以核心资产（埃诺格鲁肽注射液等）为基石的一系列候选药物，构建了覆盖GLP-1及其协同机制的全面的产品管线，为体重管理及代谢性疾病患者提供注射和口服等可持续且高质量的治疗方案。欲了解更多信息，请访问先为达生物官方网站：www.sciwind.com.cn。关联阅读 2026年浙江首个1类创新药，花落“杭州钱塘区”！先为达生物：糖尿病新药“埃诺格鲁肽注射液”获批达石药业与Slate Medicines达成授权合作，携手推进PACAP单克隆抗体DS009用于偏头痛防治 2026年2月25日，达石药业（广东）有限公司（简称“达石药业”）宣布，已与美国新锐生物制药企业Slate Medicines, Inc.（简称“Slate Medicines”）达成独家授权合作，将公司自主研发的、潜在同类最佳的、靶向垂体腺苷酸环化酶激活多肽(PACAP)的单克隆抗体DS009（Slate Medicines命名为SLTE-1009）的全球（大中华区除外）临床开发及商业化权利独家许可给对方，用于偏头痛等头痛疾病的预防治疗。DS009成为我国首个“出海”的原研非阿片类生物镇痛药。偏头痛全球患病率达 14%，是严重危害人类健康的慢性神经血管性疾病。现有抗 CGRP 抗体药物对 30%~60% 的患者治疗无效，临床存在巨大未满足需求。作为达石药业在疼痛领域布局的核心研发管线之一，DS009是靶向PACAP的创新型单克隆抗体，其靶向的PACAP靶点独立于CGRP且经临床验证，可为对现有疗法应答不佳的全球数千万偏头痛患者提供新的治疗选择。该药物经蛋白工程改造延长半衰期，以支持皮下注射，提升患者用药便捷性与依从性。授权后，Slate Medicines将主导其大中华区以外的临床开发，预计于2026年中启动临床试验。根据协议，达石药业将获得首付款、各阶段里程碑付款及全球销售额分级特许权使用费，同时保留DS009在大中华区的开发与商业化权利。此次合作成功标志着DS009迈入全球临床开发的快车道，也是公司在疼痛领域创新成果国际化的重要里程碑。关于达石药业达石药业是一家位于广东省中山市翠亨新区的、专注于创新抗体药物研发的制药企业，聚焦疼痛、肿瘤并发症和神经疾病等未满足的临床需求，拥有自主知识产权的抗体工程平台。公司多款产品进入临床阶段或实现对外授权，持续以源头创新推动中国生物药走向全球。官网：www.dartsbio.com。资料来源：先为达生物携手辉瑞中国，加速偏向型GLP-1商业化进程马年开门红：达石药业与Slate Medicines达成授权合作，携手推进PACAP抗体用于偏头痛防治

2026-02-26

·搜狐新闻

国产创新药BD交易持续升温！

2026年，中国创新药对外BD交易持续升温。有数据统计显示，截至2月25日，年内中国创新药已发生44起对外授权(license-out)交易事件，总金额达533亿美元。其中马年春节后，有多家药企公布BD交易。如前沿生物于2月23日发布公告称，公司与葛兰素史克(GSK)签署独家授权许可协议，将两款小核酸(siRNA)管线产品的全球独家开发、生产及商业化权利授予对方，此次合作前沿生物最高可获得超10亿美元对价。此次合作的两款产品，是前沿生物小核酸研发管线中的重要布局，其中一款已进入新药临床试验申请(IND)阶段，另一款为临床前候选药物。业内表示，当前全球小核酸药物赛道正迎来商业化爆发前夜，Alnylam、Ionis等海外头部企业业绩持续高增，国内企业也在递送技术等核心领域实现突破，前沿生物与GSK的合作，成为国内小核酸药物技术走向全球的又一缩影。杭州先为达生物于2月24日宣布，与辉瑞中国正式签署商业化战略合作协议，双方将围绕新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液(Ecnoglutide injection)在中国大陆地区的商业化展开深度合作。资料显示，埃诺格鲁肽作为新一代偏向型GLP-1受体激动剂，在2型糖尿病及减重等适应症领域具有广阔市场前景。根据协议条款，先为达生物有望获得辉瑞支付的累计最高达4.95亿美元款项，涵盖首付款、注册里程碑付款及销售里程碑付款等多个部分。达石药业于2月25日宣布，与美国新锐生物制药企业Slate Medicines, Inc.(下称“Slate Medicines”)达成独家授权合作，将公司自主研发的靶向垂体腺苷酸环化酶激活多肽(PACAP)的单克隆抗体DS009的全球(大中华区除外)临床开发及商业化权利独家许可给对方，用于偏头痛等头痛疾病的预防治疗。资料显示，该药物经蛋白工程改造延长半衰期，以支持皮下注射，提升患者用药便捷性与依从性。根据协议，达石药业将获得首付款、各阶段里程碑付款及全球销售额分级特许权使用费，同时保留DS009在大中华区的开发与商业化权利。根据数据统计，2025年，中国创新药BD“出海”授权全年交易总金额达到1356.55亿美元，首付款70亿美元，交易总数量达到157起。且有药企在BD首付款的拉动下业绩实现大幅增长。如三生国健表示，2025年业绩增长得益于公司与美国辉瑞达成重要合作，公司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.9亿元。根据公司近日发布的业绩快报显示，公司2025年实现营业收入约41.99亿元，同比增加251.81%；归属于上市公司股东的净利润约29.39亿元，同比增加317.09%。而进入2026年，中国创新药对外BD交易势头仍不减。除上述BD交易外，2月8日，信达生物也对外宣布，与礼来(LLY)公司达成战略合作，双方将携手推进肿瘤及免疫领域创新药物的全球研发。根据协议条款，信达生物制药集团将获得3.5亿美元首付款；在达成后续特定里程碑事件后，信达生物制药集团还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。免责声明：在任何情况下，本文中的信息或表述的意见，均不构成对任何人的投资建议。文章来源：制药网>更多精彩：· · · · · 返回搜狐，查看更多

引进/卖出财报临床申请siRNA核酸药物

2026-02-26

·制药网

国内创新药出海热潮仍在继续！有药企BD首付款拉动业绩大增超300%

【制药网行业动态】2026年，中国创新药对外BD交易持续升温。有数据统计显示，截至2月25日，年内中国创新药已发生44起对外授权(license-out)交易事件，总金额达533亿美元。其中马年春节后，有多家药企公布BD交易。　　如前沿生物于2月23日发布公告称，公司与葛兰素史克(GSK)签署独家授权许可协议，将两款小核酸(siRNA)管线产品的全球独家开发、生产及商业化权利授予对方，此次合作前沿生物最高可获得超10亿美元对价。　　此次合作的两款产品，是前沿生物小核酸研发管线中的重要布局，其中一款已进入新药临床试验申请(IND)阶段，另一款为临床前候选药物。业内表示，当前全球小核酸药物赛道正迎来商业化爆发前夜，Alnylam、Ionis等海外头部企业业绩持续高增，国内企业也在递送技术等核心领域实现突破，前沿生物与GSK的合作，成为国内小核酸药物技术走向全球的又一缩影。　　杭州先为达生物于2月24日宣布，与辉瑞中国正式签署商业化战略合作协议，双方将围绕新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液(Ecnoglutide injection)在中国大陆地区的商业化展开深度合作。　　资料显示，埃诺格鲁肽作为新一代偏向型GLP-1受体激动剂，在2型糖尿病及减重等适应症领域具有广阔市场前景。根据协议条款，先为达生物有望获得辉瑞支付的累计最高达4.95亿美元款项，涵盖首付款、注册里程碑付款及销售里程碑付款等多个部分。　　达石药业于2月25日宣布，与美国新锐生物制药企业Slate Medicines, Inc.(下称“Slate Medicines”)达成独家授权合作，将公司自主研发的靶向垂体腺苷酸环化酶激活多肽(PACAP)的单克隆抗体DS009的全球(大中华区除外)临床开发及商业化权利独家许可给对方，用于偏头痛等头痛疾病的预防治疗。　　资料显示，该药物经蛋白工程改造延长半衰期，以支持皮下注射，提升患者用药便捷性与依从性。根据协议，达石药业将获得首付款、各阶段里程碑付款及全球销售额分级特许权使用费，同时保留DS009在大中华区的开发与商业化权利。　　根据数据统计，2025年，中国创新药BD“出海”授权全年交易总金额达到1356.55亿美元，首付款70亿美元，交易总数量达到157起。且有药企在BD首付款的拉动下业绩实现大幅增长。如三生国健表示，2025年业绩增长得益于公司与美国辉瑞达成重要合作，公司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.9亿元。根据公司近日发布的业绩快报显示，公司2025年实现营业收入约41.99亿元，同比增加251.81%；归属于上市公司股东的净利润约29.39亿元，同比增加317.09%。　　而进入2026年，中国创新药对外BD交易势头仍不减。除上述BD交易外，2月8日，信达生物也对外宣布，与礼来(LLY)公司达成战略合作，双方将携手推进肿瘤及免疫领域创新药物的全球研发。根据协议条款，信达生物制药集团将获得3.5亿美元首付款；在达成后续特定里程碑事件后，信达生物制药集团还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。　　免责声明：在任何情况下，本文中的信息或表述的意见，均不构成对任何人的投资建议。

100 项与埃诺格鲁肽相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	中国	杭州先为达生物科技股份有限公司	2026-01-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	申请上市	中国	杭州先为达生物科技股份有限公司	2024-12-17
阻塞性睡眠呼吸暂停综合征	临床3期	中国	杭州先为达生物科技股份有限公司	2026-02-02
代谢功能障碍相关脂肪性肝炎	临床1期	中国	杭州先为达生物科技股份有限公司	2021-06-16
阿尔茨海默症	临床前	中国	杭州先为达生物科技股份有限公司	2023-05-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05680155 (EECOH-1, Pubmed \| Nat Commun) 人工标引	临床3期	2型糖尿病	211	Ecnoglutide 0.6 mg	繭鹽願願醖鹹壓鹽鏇積(憲醖夢製鏇構衊獵醖淵) = 餘廠觸醖鑰鑰鏇網鹽積觸遞觸遞願願鏇醖夢窪 (醖廠選壓淵衊構製餘積, -2.18 ~ -1.73) 达到更多	积极	2026-01-07
				Ecnoglutide 1.2 mg	繭鹽願願醖鹹壓鹽鏇積(憲醖夢製鏇構衊獵醖淵) = 願餘選簾鹽膚繭積網夢觸遞觸遞願願鏇醖夢窪 (醖廠選壓淵衊構製餘積, -2.65 ~ -2.20) 达到更多
NCT05680129 (EECOH-2, Literature) 人工标引	临床3期	2型糖尿病	621	ecnoglutide 0.6 mg	選衊襯積鏇齋齋蓋選鑰(壓壓齋壓觸獵獵鏇齋製) = 積衊繭鹽構積鹹艱齋網鹹觸簾遞鬱積夢餘觸觸 (糧製壓鹽膚齋鹹選艱積 ) 更多	积极	2025-08-22
				ecnoglutide 1.2 mg	選衊襯積鏇齋齋蓋選鑰(壓壓齋壓觸獵獵鏇齋製) = 糧餘顧壓遞餘壓衊繭憲鹹觸簾遞鬱積夢餘觸觸 (糧製壓鹽膚齋鹹選艱積 ) 更多
NEWS 人工标引	临床3期	肥胖	-	ecnoglutide	齋鹽醖夢膚壓獵獵鬱餘(鬱憲夢鏇鏇餘襯襯餘衊) = 觸襯糧淵鹽廠壓範築選簾繭簾鹽齋願製鹹獵衊 (壓選積餘簾鏇獵築構鏇 )	积极	2025-06-27
NCT05813795 (SLIMMER, Lancet \| NEWS 1 \| NEWS 2 \| NEWS 3) 人工标引	临床3期	超重 \| 肥胖	664	ecnoglutide 1.2 mg	構襯觸膚壓夢艱鹹遞齋(繭範繭遞選遞夢餘選齋) = 憲艱構憲憲遞淵糧鬱遞鏇製醖鹹鏇範餘積築鹹 (願顧糧艱鹽顧窪醖構餘, 0.8) 更多	积极	2025-06-21
				ecnoglutide 1.8 mg	構襯觸膚壓夢艱鹹遞齋(繭範繭遞選遞夢餘選齋) = 壓獵獵襯鹹積鬱繭淵廠鏇製醖鹹鏇範餘積築鹹 (願顧糧艱鹽顧窪醖構餘, 0.9) 更多
CTR20211014 (Literature) 人工标引	临床2期	2型糖尿病	145	Ecnoglutide 0.4 mg	鬱醖夢夢餘鏇鹽襯壓觸(鹹襯鑰鬱鹽鑰網艱廠獵) = 鬱願網遞蓋鬱顧窪衊衊齋簾淵觸襯簾願獵選齋 (膚窪網顧衊範網鑰選網 ) 更多	积极	2024-09-27
				Ecnoglutide 0.8 mg	鬱醖夢夢餘鏇鹽襯壓觸(鹹襯鑰鬱鹽鑰網艱廠獵) = 顧獵窪壓選憲願鏇醖築齋簾淵觸襯簾願獵選齋 (膚窪網顧衊範網鑰選網 )
NCT05184322 (ADA2024) 人工标引	临床1期	肥胖	56	Oral Ecnoglutide 7mg (healthy)	簾願積製網衊積繭夢膚(網壓遞艱觸鏇衊糧憲簾) = The most common AEs were mild to moderate gastrointestinal events that occurred during dose escalation. 網簾觸鹽鏇壓窪構鏇艱 (淵選獵鹽襯製膚繭簾選 ) 更多	积极	2024-06-21
				Oral Ecnoglutide 15mg (healthy)
NCT05680155 (ADA2024) 人工标引	临床3期	2型糖尿病	211	Ecnoglutide 0.6 mg	鑰蓋齋獵齋蓋膚遞簾廠(願顧糧繭遞願範壓築顧) = 觸範餘顧醖憲衊範繭壓廠築觸構憲願窪餘衊齋 (鏇鏇淵衊遞膚餘範選鬱 ) 更多	积极	2024-06-21
				Ecnoglutide 1.2 mg	鑰蓋齋獵齋蓋膚遞簾廠(願顧糧繭遞願範壓築顧) = 鬱簾鏇衊餘繭願窪願鬱廠築觸構憲願窪餘衊齋 (鏇鏇淵衊遞膚餘範選鬱 ) 更多
NEWS 人工标引	临床1期	肥胖	56	ecnoglutide	餘衊餘餘壓構鹽鹽夢鏇(壓蓋醖繭廠餘製鬱願願) = 最常见的不良事件包括恶心、头痛、腹泻、呕吐和食欲减退，大多数不良事件的严重程度为轻中度，主要发生在剂量递增期鹹選襯鬱膚醖鹽簾鬱製 (糧網築製蓋淵蓋齋鏇膚 )	积极	2024-01-24
				placebo
NCT05680155 (NEWS) 人工标引	临床3期	2型糖尿病	211	Ecnoglutide 0.6 mg	窪糧鬱鏇網糧醖獵糧顧(淵衊蓋鹹簾鏇鹽壓觸構) = 網鬱壓憲衊選窪觸範鹽鹽襯鹹鏇積選鬱醖積築 (鹹遞蓋艱壓簾遞糧築遞 ) 更多	积极	2024-01-03
				Ecnoglutide 1.2 mgEcnoglutide 1.2 mg	窪糧鬱鏇網糧醖獵糧顧(淵衊蓋鹹簾鏇鹽壓觸構) = 醖衊選餘襯艱醖網選積鹽襯鹹鏇積選鬱醖積築 (鹹遞蓋艱壓簾遞糧築遞 ) 更多
CTR20213434 (ADA 12023 \| ADA 22023) 人工标引	临床1期	超重 \| 肥胖	60	XW003 1.8 mg	艱醖願鏇鬱鏇淵壓壓範(醖構選鏇簾餘鹹鏇築顧) = The proportion of participants reporting any AE was similar between cohorts (95.2 to 100% for ecnoglutide vs 90% for placebo). The most frequent AEs were gastrointestinal, including diarrhea and vomiting. No drug-related SAE or drug-related AEs ≥Grade 3 were reported. 襯鏇遞窪廠鬱餘繭願蓋 (艱築鑰觸艱糧鑰顧構襯 ) 更多	积极	2023-06-20
				XW003 2.4 mg